Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Industry News

Luminex acquires MilliporeSigma’s flow cytometry portfolio

Jan. 14, 2019—Luminex has completed its acquisition of MilliporeSigma’s flow cytometry portfolio for $75 million. The flow cytometry portfolio includes the Amnis family of imaging flow cytometry products for cell-based analysis and the Guava portfolio of microcapillary flow cytometry systems. “The Amnis and Guava products complement our wide range of existing flow-based offerings, further differentiating our portfolio and ensuring we are well positioned to support customers today and into the future,” Homi Shamir, president and CEO of Luminex, said in

BD Max enteric panel gets FDA clearance

Jan. 11, 2019—BD announced FDA 510(k) clearance of its BD Max enteric viral panel, a molecular diagnostic test for the direct qualitative detection and differentiation of enteric viral pathogens that cause viral gastroenteritis. The panel is designed for targeted detection of the viral cause of infectious diarrhea symptoms and can detect norovirus, rotavirus, adenovirus, human astrovirus, and sapovirus. “We continue to expand our menu of unique, clinically relevant, molecular diagnostics panels to aid in diagnosis of a range of infectious

FDA clears two ePlex blood culture identification panels

Dec. 28, 2018—GenMark Diagnostics has received FDA 510(k) market clearance for its ePlex Blood Culture Identification Fungal Pathogen Panel. This panel, together with the ePlex Blood Culture Identification Gram-Positive Panel, which received FDA clearance Dec. 20, and Gram-Negative Panel were developed for the diagnosis and disease management of bloodstream infections that can lead to sepsis. “Receiving FDA clearance for two of our three ePlex BCID panels is an exciting way to end the year,” Hany Massarany, president and chief executive officer of

Beckman Coulter releases cloud-based middleware solution

Dec. 21, 2018—Beckman Coulter announced the U.S. release of its DxOne Workflow Manager, cloud-based middleware that aims to help low-volume laboratories standardize workflows, automate processes, and consolidate information. Technologists can manage samples by exception using autoverification and can get an at-a-glance view of ordering information and patient demographics on one screen. Comments and flags are readily visible, alerting users to required actions, based on laboratory-defined criteria. A sample-status overview feature directs immediate focus to items in need of attention. “We

Hycor gets clearance for Noveos allergy testing instrument

Dec. 20, 2018—Hycor Biomedical received FDA 510(k) clearance for its new allergy testing system, Noveos. Features of the system include a reduction in sample size (4 μL of serum per test), reduced blood-based interferences, less variability within allergen lots, increased accuracy, and improved walkaway time, the company reports. “Hycor has a long history of being at the forefront of allergy diagnostic testing, and we developed Noveos to be a paradigm-changing diagnostic system for laboratorians with limited options in the allergy

Twelve assays get PMA for Siemens’ Atellica

Dec. 18, 2018—Siemens Healthineers has been granted 12 premarket approvals from the FDA for its infectious disease and oncology testing menu. “These 12 PMA assays, combined with recently released High-Sensitivity Troponin I and Procalcitonin assays, provide a comprehensive menu on the Atellica Solution. Laboratories seeking a broad menu supporting the needs of their clinicians and patients can now find it on the Atellica Solution,” Deepak Nath, PhD, president of laboratory diagnostics at Siemens Healthineers, said in a statement. The infectious

Sonic buys Aurora Diagnostics

Dec. 14, 2018—Australian pathology and radiology group Sonic Healthcare will buy  Florida-based Aurora Diagnostics for $540 million. “The transaction will transform Sonic’s U.S. business, providing it with a strategic national footprint and platform that adds significant scale and extends Sonic’s existing presence in anatomic pathology,” Sonic said in a statement. Aurora has approximately 1,200 employees, including about 220 pathologists, with 32 anatomic pathology practices in 19 states.

Quest to buy lab services business of Boyce and Bynum

Dec. 13, 2018—Quest Diagnostics has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories; BBPL’s anatomic pathology division, long-term care division, and Boyce and Bynum Pathology Professional Services are not part of the transaction. Through a separate professional services agreement, BBPPS will become the exclusive pathology provider for Quest clients in Missouri and a preferred pathology provider in the greater Midwestern region. “BBPL and Quest have complementary strengths that

Qiagen launches panel, software for blood cancers

Dec. 7, 2018—Qiagen launched two novel products to deliver actionable insights on a wide range of blood cancers: a workflow for the Qiagen Clinical Insight Interpret bioinformatics solution for hematological malignancies, and the QIAact Myeloid DNA UMI Panel for use in myeloid neoplasm research using the company’s GeneReader NGS System. The QIAact myeloid panel provides an integrated sample-to-insight workflow targeting the genes and variants most relevant to onco-hematology research. It is integrated with comprehensive bioinformatics for analysis and interpretation and

Beckman Coulter rolls out DxOne Inventory Manager

Dec. 3, 2018—Beckman Coulter announced the commercial availability of the DxOne Inventory Manager, its automated, cloud-based software technology that aims to simplify inventory management and enhance operational efficiencies to help ensure timely delivery of patient test results. “For many laboratories, managing supplies involves repetitive, time-consuming, and often manual tasks. DxOne Inventory Manager eliminates the administrative aspects of supply management by automating the recording, tracking, ordering, and monitoring of consumables. This reduces workload burden, minimizes waste, and ensures stock is available

MARKETPLACE

TRENDING